CDTX Stock Summary and Trading Ideas (Cidara Therapeutics | NASDAQ:CDTX)

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's REZZAYO (rezafungin for injection) is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

Cidara Therapeutics trades on the NASDAQ stock market under the symbol CDTX.

As of April 25, 2024, CDTX stock price climbed to $12.87 with 342,424 million shares trading.

CDTX has a beta of 1.19, meaning it tends to be more sensitive to market movements. CDTX has a correlation of 0.04 to the broad based SPY ETF.

CDTX has a market cap of $58.71 million. This is considered a Micro Cap stock.

Last quarter Cidara Therapeutics reported $18 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.06.

In the last 3 years, CDTX stock traded as high as $47.80 and as low as $8.00.

The top ETF exchange traded funds that CDTX belongs to (by Net Assets): VTI, VXF, IWC.

CDTX has underperformed the market in the last year with a price return of -39.9% while the SPY ETF gained +22.6%. CDTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.7% and -30.1%, respectively, while the SPY returned +3.2% and -2.9%, respectively.

CDTX support price is $11.11 and resistance is $13.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDTX stock will trade within this expected range on the day.